

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CLARITY MEDICAL GROUP HOLDING LIMITED

清晰醫療集團控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1406)

(1) QUARTERLY UPDATE ON RESUMPTION STATUS; AND (2) CONTINUED SUSPENSION OF TRADING

This announcement is made by Clarity Medical Group Holding Limited (the “**Company**”, which together with its subsidiaries are collectively referred to the “**Group**”) pursuant to Rules 13.09(2) (a) and 13.24A of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

References are made to (i) the announcement of the Company dated 30 May 2025 in relation to the resumption guidance issued by the Stock Exchange (the “**First Resumption Guidance**”); (ii) the announcement of the Company dated 30 June 2025 in relation to the additional resumption guidance given by the Stock Exchange (together with the First Resumption Guidance, the “**Resumption Guidance**”); (iii) the announcements of the Company dated 14 July 2025, 14 October 2025, 14 January 2026, 14 April 2026 and 14 July 2026 providing quarterly updates on its business operations and resumption status; (iv) the announcements of the Company dated 25 June 2025, 11 November 2025, 12 November 2025, 6 January 2026, 13 January 2026, 5 March 2026, 2 April 2026, and 11 May 2026 respectively; (v) the announcements of the Company dated 7 April 2026 and 11 September 2026 in respect of, among other things, the key findings of independent investigation on Corporate Governance Allegations (the “**FTI Findings Announcements**”); (vi) the announcement of the Company dated 11 September 2026 in respect of the key findings of forensic investigation on the IPO Allegations (the “**GT Findings Announcement**”); (vii) the announcement of the Company dated 13 September 2026 in respect of the key findings of independent internal control review and follow-up review after the implementation of the relevant remedial measures taken by the Group (the “**IC Announcement**”); (viii) the annual results announcement dated 15 September 2026, and the annual report published on 24 September 2026, for the year ended 31 March 2025 (“**FY2025 Results**”); (ix) the interim results announcement dated 15 September 2026, and the interim report published on 24 September 2026, for the six months ended 30 September 2025 (“**2025 Interim Results**”); and (x) the annual results announcement dated 15 September 2026, and the annual report published on 24 September 2026, for the year ended 31 March 2026 (“**FY2026 Results**”, together with FY2025 Results and 2025 Interim Results, the “**Financial Results**”).

Unless otherwise stated, capitalised terms used in this announcement shall have the same meanings as those defined in the above-mentioned announcements, and all references to Rules and Chapters in this announcement are references to the rules and chapters of the Listing Rules.

UPDATE ON BUSINESS OPERATIONS

The Group continues to provide high-quality ophthalmic healthcare services in recent months. The Company maintains its technology and market leadership in Hong Kong as the only provider offering a comprehensive portfolio of advanced refractive treatments – SMILE, SMILE Pro, LASIK, SILK, and ICL.

Based on the Group's audited consolidated financial statements for FY2025 and FY2026, the Group's revenue for FY2025 and FY2026 amounted to approximately HK\$180.6 million and HK\$177.8 million, respectively. As at 31 March 2026, the Group maintained total assets of approximately HK\$170.0 million. The Group's business operations have remained substantially intact throughout the suspension period and continue to be conducted in the ordinary and usual course of business.

The Group's business has shown a sustained rebound as the impact of the earlier allegations has gradually subsided, enabling management to refocus on core operations. During the past quarter (i.e. July 2026 to September 2026), the Group's monthly revenue recorded growth of approximately 33% year-on-year, continuing its growth momentum from the previous quarter, with such growth attributable to the improving performance of its existing operations. The Group pioneered the collaboration with world-class China-based medical technology companies and took the lead in Hong Kong to introduce a new-generation thermal pulsation device for dry eye treatment and an LED-based photobiomodulation (PBM) device for myopia management. The Group remains dedicated to actively seeking partnerships and exploring cutting-edge technological collaborations.

As of the date of this announcement, the Group has continued its business operations as usual in all material respects and maintains adequate cash reserves and liquidity to meet its current ordinary course of business needs, notwithstanding that trading in the shares of the Company on the Stock Exchange has been suspended since 15 April 2025.

RESUMPTION GUIDANCE

The latest Resumption Guidance for the Company as at the date of this announcement is as follows:

- (i) the Allegations Investigation and Remedial Guidance;
- (ii) the Integrity Guidance;
- (iii) the Internal Control Guidance;
- (iv) the Corporate Governance Guidance;
- (v) the Disclosure Guidance;
- (vi) the Financial Reporting Guidance; and
- (vii) the Rule 13.24 Guidance.

UPDATE ON RESUMPTION STATUS

Pursuant to Rule 13.24A of the Listing Rules, the Board wishes to inform the Shareholders and potential investors of the progress of actions recently taken by the Company to fulfil the Resumption Guidance, and the latest development of the Group's business operations.

Allegations Investigation and Remedial Guidance

Corporate Governance Allegations

The FTI Investigation Report was submitted to the Stock Exchange. The key findings of the FTI Investigation were disclosed in the FTI Findings Announcements dated 7 April 2026 and 11 September 2026 respectively.

IPO Allegations

The GT Investigation Report was submitted to the Stock Exchange. The key findings of the GT Investigation were disclosed in the GT Findings Announcement dated 11 September 2026.

Integrity Guidance

Based on the findings of the FTI Investigation and GT Investigation, taken into account that the Company has since implemented extensive remedial measures to strengthen its internal controls and corporate governance, and that the IC Adviser has confirmed the implementation of such measures following its follow-up review, the Board (including the independent non-executive Directors) is satisfied that there is no reasonable regulatory concern regarding the integrity, competence and/or character of the Group's current management or any person with substantial influence over the Company's current management and operations, which would pose a risk to investors or damage market confidence.

Internal Control Guidance

The report on the Internal Control Review issued by the IC Adviser (which is one of the Big Four accounting firms) was submitted to the Stock Exchange. The key findings of the Internal Control Review, remedial actions implemented by the Company and the results of the follow-up review were disclosed in the IC Announcement dated 13 September 2026.

Corporate Governance Guidance

The Board and relevant Board committees are properly constituted, and the Company has restored compliance with the applicable corporate governance requirements under the Listing Rules.

Disclosure Guidance

The Company has been publishing quarterly updates on the resumption status and disclosing all material information on a timely basis to keep the Shareholders, investors and the market informed of the Group's status and latest developments in accordance with the Listing Rules.

Financial Reporting Guidance

The Company has published the Financial Results on 15 September 2026 and 24 September 2026 respectively. As such, the Company has published all the outstanding financial results as required under the Listing Rules.

The Company is in the course of preparing its interim results and interim report for the six months ended 30 September 2026.

Rule 13.24 Guidance

Since the suspension of trading of the Company's shares on the Stock Exchange and up to the date of this announcement, the Group has continued its normal business operations.

The Financial Results of the Group demonstrate the Company's compliance with Rule 13.24 of the Listing Rules. Based on the Financial Results and the Group's continued business operations, the Directors are of the view that the Group is carrying on a business with a sufficient level of operations and has assets of sufficient value to support its operations, as required under Rule 13.24 of the Listing Rules, on the basis that (i) the Group continues to operate its principal business of providing ophthalmic services in Hong Kong since listing; (ii) its scale of operations is broadly comparable to that at listing; (iii) its revenue and underlying operating performance have shown relative stability in recent years; (iv) its financial position is sufficient for a business of its nature and scale; and (v) it possesses the management expertise, operating infrastructure and governance framework necessary to support its continued operations and development.

General

On the basis of the actions taken, the Company has submitted its assessment of fulfilment of the Resumption Guidance to the Stock Exchange and continues to liaise with the Stock Exchange, including addressing subsequent queries raised during the review process, with a view to obtaining approval for the resumption of trading in the shares of the Company.

Further announcement(s) in relation to its business operations and the status of resumption will be made by the Company to inform the Shareholders and potential investors of any material development when appropriate and in accordance with the relevant requirements of the Listing Rules.

CONTINUED SUSPENSION OF TRADING

Trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on Tuesday, 15 April 2025 and will remain suspended until further notice.

Shareholders and potential investors of the Company should exercise caution when dealing in the shares or other securities of the Company, and if they are in any doubt about their position, they should consult their independent professional adviser(s).

CLARITY MEDICAL GROUP HOLDING LIMITED
JIANG Bo

Executive Director and Chief Executive Officer

Hong Kong, 12 October 2026

As at the date of this announcement, the Board comprises Mr. JIANG Bo and Mr. CAO Jian as executive Directors, Mr. CHEN Jiarong, Professor WANG Qinmei and Mr. SUN Peng as non-executive Directors, and Mr. WANG Can, Ms. CI Ying, Dr. CHEN Poujian and Mr. XU Anliang as independent non-executive Directors.